PharmiWeb Recruiter Blog

Global Bayer Co.Lab network of life science incubators established to accelerate innovation and foster collaborations within vibrant biotech ecosystems / U.S. flagship location opening in Cambridge, MA, encompasses state-of-the-art laboratories and collaborative working space designed specifically to support entrepreneurs focused on developing the next generation of cell and gene therapies / Bayer’s Co.Lab Cambridge co-located with the Bayer Research and Innovation Center (BRIC), BlueRock Therapeutics, and Leaps by Bayer, allowing for direct access to Bayer’s experts / Investment part of Bayer’s continued strategic investment in the U.S.

• The Institute of Human Biology aims to better predict which drug candidates are safe and most effective in patients by evolving and increasing the use of human model systems.
• Human model systems are miniature living 'replicas' of human tissues and organs that also have the potential to reduce reliance on animal testing.
• The institute brings together scientists from academia and industry to lead the broad adoption of human model systems in pharmaceutical R&D as well as in clinical practice.

Basel, 4 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the Institute of Human Biology (IHB) focussing on advancing research in the field of human model systems such as organoids. Leveraging human model systems, the institute aims to accelerate drug discovery and development by improving the understanding of how organs function and how diseases develop. Ultimately, this will help to bring medicines to patients faster. These efforts will also enable early testing of which drug candidates are safe and which molecules would work best for each patient.

National Biotechnology Company Adds New Location in Louisiana

• Abbott's CentriMag™ Blood Pump, previously cleared for use up to six hours, now can be used to provide longer-term life support to critically ill patients, providing doctors more time to make critical care decisions
• Abbott's CentriMag™ Pre-connected Pack, which combines a blood pump and oxygenator to form a life support circuit, also received FDA clearance for life support lasting less than six hours, helping physicians provide urgent critical care more efficiently and in fewer steps

ABBOTT PARK, Ill., April 25, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. With the new indication, the CentriMag Blood Pump for use with the CentriMag™ System, is now cleared for longer-term use in adults when extracorporeal membrane oxygenation (ECMO) – a type of life support for people whose heart and lungs are not working – is critical to saving their life. Now, the clearance for longer-term support allows physicians more time to assess next steps and make critical care decisions for their patients.

• Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date
• Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account for approx. 50 percent of the company’s research pipeline
• New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists

Boehringer Ingelheim today inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. The new high-tech facility underlines the company’s strong commitment to Germany and Europe as location for research and development (R&D) for the care of patients around the world. With the investment of 350 million EUR, Boehringer Ingelheim significantly enhances its innovation power and development of biopharmaceutical development capabilities in Germany.

Bern, Switzerland and Boston, U.S.A., 21 April, 2023 – RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is excited to announce a new partnership with Boehringer Ingelheim. The companies aim to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery^® platform and AI tools with Boehringer Ingelheim’s research in retinal diseases.

• A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund
• Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its recently appointed Impact Council
• In three years' time, Gilde Healthcare raised over €1.5 billion across three funds

UTRECHT, Netherlands, April 19, 2023 /PRNewswire/ -- Gilde Healthcare today announces a new investment fund with €600 million in commitments: Gilde Healthcare Venture&Growth VI. The new fund focuses on fast growing companies developing solutions for better care at lower cost. Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, medical technology (MedTech) and therapeutics.

In addition to $3.7 billion investment in Boone County, Lilly will commit $15 million to Ivy Tech to foster a diverse talent pipeline for high-tech manufacturing jobs

• PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions
• Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology

RAHWAY, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

A pioneering biotech firm has secured £13.2 million to fund its mission to develop the world’s first treatment for a rare, incurable and deadly disease.